Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519131 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1EPHX1CA12CA1 | |
| SCHEMBL5512591 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1EPHX1CA12CA1 | |
| SCHEMBL15668891 | 0.85 | EPHX1 (0.48) | SMN1; SMN2ALDH1A1EPHX1CYP2C9CYP2C19 | |
| SCHEMBL7120046 | 0.85 | EPHX1 (0.48) | SMN1; SMN2ALDH1A1EPHX1CYP2C9CYP2C19 | |
| SCHEMBL19690600 | 0.85 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1EPHX1CA12CA1 | |
| SCHEMBL16586374 | 0.84 | EPHX1 (0.40) | SMN1; SMN2ALDH1A1EPHX1CA12CA1 | |
| SCHEMBL10599727 | 0.84 | EPHX1 (0.40) | SMN1; SMN2ALDH1A1EPHX1CA12CA1 | |
| SCHEMBL30093936 | 0.83 | EPHX1 (0.44) | SMN1; SMN2ALDH1A1EPHX1CYP2C9CYP2C19 | |
| SCHEMBL6843635 | 0.83 | EPHX1 (0.43) | SMN1; SMN2ALDH1A1EPHX1CA12CA1 | |
| SCHEMBL10879040 | 0.83 | ATM (0.41) | SMN1; SMN2ALDH1A1EPHX1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716159-B1 | BICYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS | MOMENTIVE PERFORMANCE MAT INC (US) | 2011-07-13 | — | — | EP | claimed |
| EP-1697386-B1 | ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES | GEN ELECTRIC (US) | 2007-10-10 | — | — | EP | claimed |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4488271-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-01-08 | — | — | EP | disclosed |
| US-20240244957-A1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | Merck Patent KGaA (DE) | 2024-07-18 | — | — | US | disclosed |
| EP-3475372-B1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | MERCK PATENT GMBH (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3807367-B1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20230151235-A1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | MERCK PATENT GMBH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-11603479-B2 | Formulation of an organic functional material | MERCK KGAA (DE) | 2023-03-14 | — | — | US | disclosed |
| US-11407907-B2 | Formulation of an organic functional material | MERCK PATENT GMBH (DE) | 2022-08-09 | — | — | US | disclosed |
| EP-2145042-B2 | TEXTILE SCENTING | HENKEL AG & CO KGAA (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| WO-2008012140-A1 | LIQUID SUPPORT | HENKEL AG & CO. KGAA (DE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008003631-A1 | WASHING, CLEANING AND CARE PRODUCTS | HENKEL AG & CO. KGAA (DE) | 2008-01-10 | — | — | WO | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2007028477-A1 | CONSUMER PRODUCTS HAVING VARYING ODOR PATTERNS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-15 | — | — | WO | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SMN1; SMN2 4172/4885ALDH1A1 4407/4885EPHX1 3431/4885 |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | HPGDS, PTGIS, HPGD | SMN1; SMN2 4662/4885ALDH1A1 475/4885EPHX1 1169/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SMN1; SMN2 4172/4885ALDH1A1 4407/4885EPHX1 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.